Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302103 | 0.85 | TUBB1 (0.33) | TUBB1FFAR1FFAR4PAX8PDGFRB | |
| SCHEMBL4311273 | 0.80 | FFAR1 (0.31) | FFAR1FFAR4 | |
| SCHEMBL4306354 | 0.80 | PDE1A (0.36) | FFAR1FFAR4 | |
| SCHEMBL13662920 | 0.77 | PDE3B (0.36) | FFAR1FFAR4ACHE | |
| SCHEMBL548615 | 0.74 | FFAR1 (0.36) | TUBB1FFAR1FFAR4PAX8PTGS2 | |
| SCHEMBL28298864 | 0.73 | ACHE (0.36) | TUBB1FFAR1FFAR4PDGFRBPDGFRA | |
| SCHEMBL8736820 | 0.69 | TAAR1 (0.44) | TUBB1FFAR1FFAR4 | |
| SCHEMBL13664495 | 0.69 | TUBB1 (0.31) | TUBB1FFAR1FFAR4 | |
| SCHEMBL2728871 | 0.69 | HSD17B10 (0.35) | TUBB1 | |
| SCHEMBL16256381 | 0.69 | ACHE (0.36) | TUBB1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | BCAT1, BCAT2, AADAT | TUBB1 71/4885FFAR1 1468/4885FFAR4 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.